Serum CrossLaps as Bone Resorption Marker in Peritoneal Dialysis

Negri, Armando; Quiroga, Mabel Alvarez; Bravo, Marina; Marino, A; Fradinger, Erich; Bogado, César E.; Zanchetta, José R.

doi:10.1177/089686080202200518

Cited by 7 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum CTX was shown to be useful as a bone resorption marker for monitoring the response in individuals undergoing antiresorptive therapy for osteoporosis (24), and it was also shown to predict hip fractures in elderly women in the EPIDOS study (25). We have recently shown that serum CTX is the bone resorption marker that better correlates with bone remodeling estimated by serum iPTH levels (26).…”

Section: Discussionmentioning

confidence: 99%

Bone Mineral Density: Serum Markers of Bone Turnover and Their Relationships in Peritoneal Dialysis

Negri

Barone²,

Quiroga³

et al. 2004

Perit Dial Int

Self Cite

View full text Add to dashboard Cite

Background The usefulness of bone mass measurements and bone turnover markers to estimate the risk of fracture and the type of underlying renal osteodystrophy are not well established in patients on peritoneal dialysis (PD). Objective To assess bone mass using total and regional bone densitometry in a group of patients on PD and to determine if serum markers of bone turnover identify patients with low bone mass. Methods Bone densitometry was studied by dual-energy x-ray absorptiometry (DEXA), and bone turnover using several serum markers, in 65 patients on PD. Bone mass was classified as normal, osteopenic, or osteoporotic according to World Health Organization criteria based on bone mineral density (BMD) T scores. Results T scores in the osteopenia range were present at the lumbar spine (LS) in 44.6% (45% of men and 44.4% of women) of patients and at the femoral neck (FN) in 56.9% (55% of men and 58% of women). T scores in the osteoporosis range were present at the LS in 13.8% of patients (10% of men and 15.5% of women) and at the FN in 21.5% (30% of men and 17.7% of women). Patients with BMD T scores in the osteoporosis range at both regions had increased serum intact parathyroid hormone (iPTH) levels compared to patients in the osteopenic/normal range. Bone mineral content in the whole skeleton (TBMC) correlated negatively with iPTH ( r = –0.34) and with total time on dialysis ( r = –0.26); in multivariate analysis, only iPTH correlated negatively with TBMC ( B = –0.26, p = 0.03). No correlations were found between the other bone markers and BMD T scores at the FN or LS. There were no significant differences in absolute BMD or BMD T scores at the LS or FN between patients with and patients without fractures. Conclusions BMD T scores in the osteopenia/osteoporosis range were observed at the LS in 58.4% of these patients on PD and at the FN in 78.4%. TBMC correlated negatively with iPTH. There were no correlations between markers of bone turnover and bone mass measurements at the two skeletal regions, although patients with BMD T scores in the osteoporosis range had increased serum iPTH levels. Bone mass measurements were not different between patients with and patients without fractures.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Mineral Density: Serum Markers of Bone Turnover and Their Relationships in Peritoneal Dialysis

Negri

Barone²,

Quiroga³

et al. 2004

Perit Dial Int

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mean levels of bone turnover markers are elevated in chronic renal failure. There are marked increases in osteocalcin, cross‐linked telopeptide of type I collagen (ICTP), and CrossLaps (beta‐carboxyterminal telopeptide of type I collagen), all cleared by the kidney (77,78).…”

Section: Bone Turnover Markers and Pthmentioning

confidence: 99%

Reviews: Altered Laboratory Findings Associated with End‐Stage Renal Disease

Robitaille¹,

Lafrance

Leblanc

2006

Seminars in Dialysis

View full text Add to dashboard Cite

Several laboratory parameters can be altered in advanced renal failure. Results may be difficult to interpret and may become misleading and unreliable in such a context. On the other hand, some of the alterations may reflect real abnormalities. Thus sufficient knowledge and careful judgment are required by the clinician. We reviewed different publications related to biochemical anomalies in renal failure and report some of the main findings. The sections are divided as follows: cardiovascular risk factors and markers, inflammation markers, pancreatic and liver function tests, hormones, bone turnover indices and parathyroid hormone assays, tumor markers, carbohydrate metabolism indicators, and others. The information provided should be useful to clinicians involved in the care of renal failure patients.

show abstract